Literature DB >> 12133042

Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache.

M E Bigal1, F D Sheftell, A M Rapoport, R B Lipton, S J Tepper.   

Abstract

The International Headache Society (IHS) has been criticized for its approach to classification of chronic daily headache (CDH); Silberstein and Lipton criteria provide an alternative to this approach. The aim of this study is to apply the alternative diagnostic approaches to a sample of CDH patients consulting in specialty care. Our sample consisted of 638 patients with CDH. Patients were classified according to both classification systems. Patients were predominantly female (65.0%), with ages ranging from 11 to 88 years. According to the Silberstein and Lipton classification, we found eight different diagnoses. The most common diagnosis was chronic migraine (87.4%), followed by new daily persistent headache (10.8%). Just six patients had chronic tension-type headache (CTTH). Applying the IHS criteria we found 14 different diagnoses. Migraine was found in 576 (90.2%) patients. CTTH occurred in 621 (97.3%), with only 10 (1.57%) having this as the sole diagnosis. We conclude that both systems allow for the classification of most patients with CDH when daily headache diaries are available. The main difference is that the IHS classification is cumbersome and requires multiple diagnoses. The Silberstein and Lipton system is easier to apply, and more parsimonious. These findings support revision of the IHS classification system to include chronic migraine.

Entities:  

Mesh:

Year:  2002        PMID: 12133042     DOI: 10.1046/j.1468-2982.2002.00384.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  16 in total

Review 1.  New daily persistent headache.

Authors:  Todd D Rozen
Journal:  Curr Pain Headache Rep       Date:  2003-06

2.  Genomic expression patterns in medication overuse headaches.

Authors:  Andrew D Hershey; Danny Burdine; Marielle A Kabbouche; Scott W Powers
Journal:  Cephalalgia       Date:  2010-06-02       Impact factor: 6.292

3.  The future of migraine: beyond just another pill.

Authors:  Roger K Cady
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

Review 4.  New daily persistent headache in children and adolescents.

Authors:  Eric P Baron; A David Rothner
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

5.  Levetiracetam in the preventive treatmentof transformed migraine: A prospective, open-label, pilot study.

Authors:  Alan M Rapoport; Fred D Sheftell; Stewart J Tepper; Marcelo E Bigal
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

Review 6.  Tension-type headache: why does this condition have to fight for its recognition?

Authors:  Rigmor Jensen; Lars Bendtsen
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 7.  Chronic migraine: epidemiology and disease burden.

Authors:  Aubrey N Manack; Dawn C Buse; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2011-02

8.  Refractory migraine in a headache clinic population.

Authors:  Pablo Irimia; Jose-Alberto Palma; Roberto Fernandez-Torron; Eduardo Martinez-Vila
Journal:  BMC Neurol       Date:  2011-08-01       Impact factor: 2.474

9.  Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.

Authors:  Chun-Pai Yang; Bing-Yan Zeng; Ching-Mao Chang; Po-Hsuan Shih; Cheng-Chia Yang; Ping-Tao Tseng; Shuu-Jiun Wang
Journal:  Neurotherapeutics       Date:  2021-09-27       Impact factor: 6.088

10.  The classification of chronic daily headache in French children and adolescents: a comparison between the second edition of the International Classification of Headache Disorders and Silberstein-Lipton criteria.

Authors:  Jean-Christophe Cuvellier; Frédéric Couttenier; Stéphane Auvin; Louis Vallée
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.